AI agents that run your enterprise workflows and get measurably better over time. 150+ enterprises live in production across retail, insurance, and financial services. Backed by Accel and General Catalyst.
About the role
We are seeking an accomplished scientific leader who will define and drive our in vitro screening and pharmacological characterization capability for Degrader Antibody Conjugates (DACs). Our DAC platform pairs antibody-based targeting with our degrader expertise to direct protein degradation to specific cell types, and this scientist will own the in vitro strategy defining how candidate molecules move through the screening cascade — from primary screening through mechanistic pharmacological characterization of...
What they're looking for
- Demonstrated experience designing and setting up in vitro pharmacology studies and screening cascades, prior experience building screening/assay cascades in the ADC or DAC field is strongly preferred
- Demonstrated leadership in a matrixed, cross-functional environment, with the ability to influence, align, and drive teams and programs
- Excellent communication and presentation skills, with a track record of clearly conveying complex science and recommendations to project teams and senior leadership
- Experience with mechanistic assays that dissect DAC activity, such as antibody binding and intracellular drug release, is highly desired
- Familiarity with automation equipment (e.g., liquid handlers) and automated workflows
- Strong analytical and problem-solving skills, with sound judgment in evaluating and interpreting experimental data
More about this role
Senior Scientist - Degrader Antibody Conjugate Cellular
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
We are seeking an accomplished scientific leader who will define and drive our in vitro screening and pharmacological characterization capability for Degrader Antibody Conjugates (DACs). Our DAC platform pairs antibody-based targeting with our degrader expertise to direct protein degradation to specific cell types, and this scientist will own the in vitro strategy defining how candidate molecules move...
Browse similar: AI jobs · AI startup jobs · Startup jobs